OPG is being investigated as a potential biomarker in specific disease contexts, such as inflammatory bowel disease and cardiovascular disease, but it is not currently recommended by any major clinical guidelines as a standard marker of inflammation [31,35]. Here, TNFRSF11B is linked to inflammatory bowel disease.